Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Bipartisan legislation could help patients access necessary prescription drugs by potentially reducing the financial burden that results from complex and hard-to-navigate health insurance plans
Funding will support preclinical research and early-stage clinical trials
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
White will be the first person living with CF to lead the Board into a new era of CF
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies